2023-510559-41-00暂停2 期
A phase II study evaluating the efficacy and the safety of TPEx followed by a maintenance with the combination of avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN).
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 入组人数
- 70
- 试验地点
- 20
- 主要终点
- Overall survival (OS) defined as the time between inclusion and death from any cause or the last follow-up contact for patients who are alive.
研究概览
简要总结
To estimate the efficacy in terms of overall survival.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Adult men and women ≥ 18 years and < 75 years.
- •Calcium levels must be normalized and maintained within normal limits for study entry. Medical management of calcium levels is permitted. Note: Normal calcium levels may be based on ionized calcium or adjusted for albumin.
- •Histologically confirmed recurrent and/or metastatic SCCHN (oral cavity, pharynx, larynx), not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy); squamous cell carcinoma of unknown primary if HPV positive.
- •Detection of PD-L1 protein expression in formalin-fixed, paraffin-embedded (FFPE) SCCHN tissue samples determined by Combined Positive Score (CPS) ≥1 using local IHC assay.
- •Patients with Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Patients without contra indication to TPEx (either with cisplatin or carboplatin), to docetaxel, cetuximab and to immunotherapy (avelumab).
- •Documentation of p16 status as surrogate of human papillomavirus (HPV) status of tumor for SCC of the oropharynx.
- •Measurable disease by CT or MRI per RECIST 1.1 criteria.
- •In case of radiotherapy given without systemic treatment, prior curative radiation therapy must have been completed at least 4 weeks before TPEx administration and/or prior palliative radiotherapy must have been completed at least 2 weeks before TPEx administration.
- •Screening laboratory values must meet the following criteria (using NCI-CTCAE v5) and should be obtained within 14 days prior to eligibility check: a. WBC > 2000/μL b. Polynuclear neutrophils >1.5 x 109/L c. Platelets > 100 x 109/L d. Hemoglobin > 9.0 g/dL e. ALAT/ASAT< 3.0 x ULN in the absence of liver metastases or < 5x ULN in the presence of liver metastases f. Bilirubin < 1.5 x ULN (except Gilbert Syndrome: < 3.0 mg/dL) g. Creatinine clearance > 60 mL/min (measured or calculated by preferably Cockcroft and Gault formula) for cisplatin administration and creatinine clearance ≥ 40 mL/min (measured or calculated by preferably Cockcroft and Gault formula) for carboplatin administration.
排除标准
- •Prior systemic chemotherapy for the head and neck carcinoma, except if given as part of a multimodal treatment for locally advanced disease which was completed more than 6 months prior to study entry.
- •Histologically confirmed recurrent or metastatic carcinomas of the nasopharynx, squamous cell carcinoma of unknown HPV negative primary, or salivary gland or non-squamous histologies (e.g., mucosal melanoma) are not allowed.
- •Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.
- •Prior malignancy active within the previous 3 years except for head and neck cancers and locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
- •Subjects with active, known or suspected autoimmune disease. Subjects with stabilized type I diabetes mellitus under treatment, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •Subjects with a condition requiring systemic chronic administration of corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of eligibility check. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •Patients having received prior therapy with anti-PD1, anti-PD-L1(or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- •Prior anti-EGFR treatment received less than 6 months before eligibility check.
结局指标
主要结局
Overall survival (OS) defined as the time between inclusion and death from any cause or the last follow-up contact for patients who are alive.
Overall survival (OS) defined as the time between inclusion and death from any cause or the last follow-up contact for patients who are alive.
次要结局
- Progression free survival (PFS) defined as the time between inclusion and first progression according to RECIST 1.1.
- Incidence and severity of adverse events and serious adverse events during maintenance by the combination of cetuximab and avelumab and until 3 months after the last administration of maintenance (or until the start of a second line treatment if it starts before 3 months) as graded by the NCI Common Terminology Criteria of Adverse Events (NCI-CTCAE) v 5.0.
研究者
Dr Caroline EVEN
Scientific
Groupe Oncologie Radiotherapie Tete Cou
研究点 (20)
Loading locations...
相似试验
已完成
2 期
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabPreviously Treated Metastatic Adenocarcinoma of the PancreasNCT02243371Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins93
终止
2 期
A Phase II Study of Dacomitinib in Progressive Brain MetastasesBrain CancerNCT02047747David Piccioni, M.D., Ph.D4
已完成
2 期
Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced HepatocarcinomaAdvanced HepatocarcinomaNCT01418729Hospital Donostia216
已完成
2 期
Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical ResectionGlioblastoma MultiformeNCT01006044Clinica Universidad de Navarra, Universidad de Navarra26
进行中（未招募）
1 期
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000015841EUCTR2016-005115-41-HUTransgene S.A.39